Rutgers Cancer Institute of New Jersey names chief of blood disorders
Click Here to Manage Email Alerts
Matthew Matasar, MD, MS, has been named chief of blood disorders at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health.
Matasar will oversee the institute’s transplant and cell therapy, hematologic malignancies and benign hematology sections.
Matasar, whose appointment will take effect in November, also will serve as professor of medicine at Rutgers Robert Wood Johnson Medical School.
“I am thrilled for the opportunity to join New Jersey’s only NCI-designated comprehensive cancer center to help continue to build on a strong foundation of excellence in stem cell transplantation and cellular therapy research, clinical practice, and clinical trials for our patients at both Rutgers Cancer Institute and across RWJBarnabas Health,” Matasar said in a press release. “I am so excited to help guide the growth of our program, which stands on the pillars of clinical excellence, discovery and innovation, education, health equity and community engagement. The care of patients facing a diagnosis of a blood disorder is evolving at breathtaking speed, and I am confident that our growing team will continue to lead in driving this change.”
Matasar received his medical degree from Harvard Medical School and trained in internal medicine at NewYork-Presbyterian/Columbia University Medical Center. He spent the past 14 years at Memorial Sloan Kettering Cancer Center, where he held several leadership positions.
In his new role, Matasar will lead the enhancement of multi-disciplinary clinical services and clinical research activities across the health system, while also collaborating with colleagues across RWJBarnabas Health in an effort to increase access to clinical trials.
“Dr. Matasar is among the nation’s most experienced clinicians and researchers in routine, rare and complex hematologic malignancies, with extensive expertise in treating these types of cancers with clinical trials, immunotherapy and other cellular therapies,” Steven K. Libutti, MD, FACS, senior vice president of oncology services at RWJBarnabas Health, said in the release. “His vast leadership accomplishments complement our wide-ranging scope as an NCI-designated comprehensive cancer center, and we look forward to Dr. Matasar implementing his vision, which will further elevate the stature of our hematologic malignancies and cellular therapy programs nationwide.”
Read more about
Click Here to Manage Email Alerts